Nobody has the most critical piece of information - nor can they get it:
What does the committee deem to be a success in order to recommend approval?
These children with SR-aGVHD have no other treatment options; Rem-L displays efficacy in a significant proportion of these children.
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-501
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |